Clinical trial
Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With…
NCT02601313 · Kite, A Gilead Company, Industry · Completed
Key facts
| NCT number | NCT02601313 |
|---|---|
| Title | Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2) |
| Official title | A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects With Relapsed/Refractory Mantle Cell Lymphoma |
| Acronym | ZUMA-2 |
| Lead sponsor | Kite, A Gilead Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Relapsed/Refractory Mantle Cell Lymphoma |
| Intervention type | Biological, Drug |
| Interventions | brexucabtagene autoleucel, Cyclophosphamide, Fludarabine, Axicabtagene Ciloleucel |
| Enrollment | 105 |
| Start date | Nov 9, 2015 |
| Primary completion | Sep 22, 2023 |
| Completion | Sep 22, 2023 |
| First posted | Nov 10, 2015 |
| Last update posted | Jan 14, 2025 |
| Countries | France, Germany, Netherlands, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: